Deciphera Receives European Commission Approval Of Romvimza (Vimseltinib)

Refinitiv1분 미만 읽기

Ono Pharmaceutical Co Ltd 4528:

DECIPHERA RECEIVES EUROPEAN COMMISSION APPROVAL OF ROMVIMZA™ (VIMSELTINIB) FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오